Prediction-FREE Neoantigen Validation Enables TP53-targeted Personalized Cancer Therapeutics

Prediction-FREE Neoantigen Validation Enables TP53-targeted Personalized Cancer Therapeutics

2021–Direct Quantification of Neoantigens Like Never Before — published on Science

Genetic changes in human genome are the driving force for all cancers. Different patients have different sets of mutation profiles even for the  patients who all have the same disease. For decades, doctors, cancer researchers, and pharmaceutical companies have been working tirelessly trying to find a way to treat each person’s unique disease in a highly personalized way that will reach the maximum treatment efficacy with the lowest side effects. Complete Omics, working with leaders in cancer therapeutics, has developed pipelines based on our multi-omics techniques through which we clearly observe and quantify personalized therapeutic targets encoded by the most frequently mutated tumor suppressor gene TP53. We validated and quantified the TP53 neoantigens on the surfaces of cancers and provided information to healthcare providers to support their decision on if or not to adopt a highly personalized cancer treatment targeting these neoantigens and when to use it (Ref 1). These findings provided the 1st-hand evidence for cancer therapeutics without the uncertainty that comes with predictions.

  1. Publication: Targeting a neoantigen derived from a common TP53 mutation.
Follow by Email
Facebook
Twitter
LinkedIn